<h2 dir="ltr">Intravenous Immunoglobulin (IVIG)</h2>
Intravenous Immunoglobulin (IVIG) is a blood product made from pooled antibodies (immunoglobulins) collected from healthy donors. It is used to treat a variety of autoimmune, inflammatory, and immunodeficiency disorders by boosting the immune system or regulating immune responses.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total diagnosed prevalent cases of selected indications
</li>
<li dir="ltr" aria-level="1">
Total Target Patient Pool by Indications
</li>
<li dir="ltr" aria-level="1">
Total Treated Patients by Indications
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/intravenous-immunoglobulin-ivig-epidemiology-forecast">Intravenous Immunoglobulin Target Patient Pool &ndash; U.S. (2024 Estimates)</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Primary Immunodeficiency Diseases &ndash; ~203K cases
</li>
<li dir="ltr" aria-level="1">
Immune Thrombocytopenic Purpura (ITP) &ndash; ~58K cases
</li>
<li dir="ltr" aria-level="1">
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) &ndash; ~21K cases
</li>
<li dir="ltr" aria-level="1">
Multifocal Motor Neuropathy (MMN) &ndash; 1.8K cases
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market">Intravenous Immunoglobulin Cancer Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In September 2024, GC Biopharma USA launched ALYGLO (10% IVIG) for adults (&ge;17 years) with Primary Immunodeficiency (PI)
</li>
<li dir="ltr" aria-level="1">
BIVIGAM generated approx. USD 50 million in U.S. revenue in 2024
</li>
</ul>
<h3 dir="ltr">Intravenous Immunoglobulin Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The growing incidence of primary immunodeficiency diseases (PI), immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and other autoimmune conditions is driving steady demand for IVIG therapies worldwide.
</li>
<li dir="ltr" aria-level="1">
Increasing use of IVIG in off-label indications such as Kawasaki disease, myasthenia gravis, and Guillain-Barr&eacute; syndrome is widening the market scope, supported by emerging clinical data and physician preference for immunomodulatory treatment options.
</li>
</ul>
<h3 dir="ltr">Intravenous Immunoglobulin Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
IVIG production depends on human plasma donations, making the supply chain vulnerable. The complex, time-intensive manufacturing process further limits scalability and contributes to product shortages.
</li>
<li dir="ltr" aria-level="1">
IVIG therapies are expensive biologics, often facing payer resistance, particularly for off-label use. This limits access, especially in cost-sensitive healthcare systems, and impacts pricing flexibility and patient coverage.
</li>
</ul>
<h3 dir="ltr">Intravenous Immunoglobulin Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
PlasmaCap IG
</li>
<li dir="ltr" aria-level="1">
TAK-880
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr">Intravenous Immunoglobulin Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Shanghai RAAS Blood Products Co. Ltd
</li>
<li dir="ltr" aria-level="1">
Octapharma AG
</li>
<li dir="ltr" aria-level="1">
Takeda Pharmaceutical Company Limited
</li>
<li dir="ltr" aria-level="1">
Baxter International Inc.
</li>
<li dir="ltr" aria-level="1">
Bayer AG
</li>
<li dir="ltr" aria-level="1">
Bio Products Laboratory Ltd
</li>
<li dir="ltr" aria-level="1">
Biotest AG
</li>
<li dir="ltr" aria-level="1">
CSL Behring
</li>
<li dir="ltr" aria-level="1">
Grifols SA
</li>
<li dir="ltr" aria-level="1">
Kedrion SpA
</li>
<li dir="ltr" aria-level="1">
LFB Biotechnologies SAS
</li>
<li dir="ltr" aria-level="1">
BDI Pharma Inc.
</li>
<li dir="ltr" aria-level="1">
China Biologic Products Holdings Inc.
</li>
<li dir="ltr" aria-level="1">
Hualan Biological Engineering Inc.
</li>
<li dir="ltr" aria-level="1">
ADMA Biologics Inc.
</li>
</ul>
And others.

Intravenous Immunoglobulin (IVIG) Market

Intravenous Immunoglobulin (IVIG) Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape